Company / PP&E (Net)
Arcadia Biosciences, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$8.0K
FY2025
5-year range
$8.0K / $2.3M
FY2021-FY2025
Trend
-80.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 5 consecutive years, from $4M in FY2020 to $8,000 in FY2025.
Based on SEC 10-K filings.
$8,000 in FY2025 with a 5-year CAGR of -70.4%.
Declined from $384,000 to $8,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -77.5%
- 5-Year CAGR
- -70.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcadia Biosciences, Inc.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -70.4%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 80.5% year-over-year.
- Peak pp&e (net) was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.0K | -80.5% |
| FY2024 | $41.0K | -89.3% |
| FY2023 | $384.0K | -45.5% |
| FY2022 | $704.0K | -69.3% |
| FY2021 | $2.3M | -35.3% |
| FY2020 | $3.5M | +96.7% |
| FY2019 | $1.8M | +355.4% |
| FY2018 | $395.0K | +32.1% |
| FY2017 | $299.0K | -41.1% |
| FY2016 | $508.0K | -13.2% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026